Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma

Abstract

Purpose:

To assess the effectiveness and safety of adjunctive topical netarsudil 0.02% and latanoprostene bunod 0.024% in patients with glaucoma.

Methods:

A retrospective, multi-center, cohort study of patients with glaucoma treated with netarsudil 0.02% or latanoprostene bunod from five tertiary care centers. Inclusion criteria included patients with glaucoma treated with either medication as adjunctive therapy. Outcomes included mean absolute intraocular pressure (IOP) reduction and relative IOP reduction from baseline. Adverse reactions and reasons for discontinuation were reported. One-way analysis of variance, Kruskal-Wallis rank sum test, and Mann Whitney U test compared the outcomes.

Results:

A total of 95 eyes (95 patients) on netarsudil and 41 eyes (41 patients) on latanoprostene bunod were analyzed. Mean duration of use was 54.3 ± 28 days for netarsudil and 82.9 ± 51.2 days for latanoprostene bunod. At the final visit, mean IOP reduction was 3.9 ± 4.6 mmHg (17.5 ± 6.0%) (p < 0.0001) with netarsudil and 2.9 ± 3.7 mmHg (13.6 ± 16.3%) (p < 0.0001) with latanoprostene bunod. IOP lowering did not depend on baseline number of IOP-lowering medications. The most common reason for discontinuation was non-effectiveness in both groups

Conclusion:

Similar to monotherapy, netarsudil and latanoprostene bunod demonstrated efficacy in lowering IOP when used as adjunctive therapy.

Keywords

Glaucoma latanoprostene bunod netarsudil rhopressa vyzulta

Get full access to this article

View all access options for this article.

References

Weinreb

Khaw

PT.

Primary open-angle glaucoma. Lancet 2004; 363: 1711–1720.

Primary Open-Angle Glaucoma PPP - 2015. American Academy of Ophthalmology, https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp-2015 (2015, accessed 21 July 2019).

Ren

, et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci 2016; 57: 6197–6209.

Lin

C-W

Sherman

Moore

, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther 2018; 34: 40–51.

Hoy

SM.

Netarsudil ophthalmic solution 0.02%: first global approval. Drugs 2018; 78: 389–396.

Cavet

Vollmer

Harrington

, et al. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci 2015; 56: 4108–4116.

Krauss

AHP

Impagnatiello

Toris

, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res 2011; 93: 250–255.

Weinreb

Liebmann

Martin

, et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma 2018; 27: 7–15.

Kawase

Vittitow

Weinreb

, et al. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther 2016; 33: 1612–1627.

10.

Serle

Katz

McLaurin

, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol 2018; 186: 116–127.

11.

Shaw

Sang

Wang

, et al. Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury. Exp Eye Res 2017; 158: 33–42.

12.

Weinreb

Sforzolini

Vittitow

, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology 2016; 123: 965–973.

13.

Medeiros

Martin

Peace

, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol 2016; 168: 250–259.

14.

Inazaki

Kobayashi

Anzai

, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol 2017; 255: 2009–2015.

15.

Weinreb

Ong

Sforzolini

, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99: 738–745.

16.

Wang

R-F

Williamson

Kopczynski

, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma 2015; 24: 51–54.

17.

Kiel

Kopczynski

CC.

Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther 2015; 31: 146–151.

18.

Garcia

Ngai

Mosaed

, et al. Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clin Ophthalmol 2016; 10: 2035–2050.

19.

Hoy

SM.

Latanoprostene bunod ophthalmic solution 0.024%: a review in open-angle glaucoma and ocular hypertension. Drugs 2018; 78: 773–780.

20.

Neelakantan

Vaishnav

Iyer

, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma 2004; 13: 130–136.

21.

Inazaki

Kobayashi

Anzai

, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma 2017; 26: 96–100.

22.

Moumneh

Sheybani

Fellman

, et al. Reticular corneal edema or corneal honeycombing in eyes treated with netarsudil: a case series. J Glaucoma 2020; 29(7): 607–610.